US · Healthcare · Biotechnology
EPS came in at -0.94 against a street estimate of -1.10 — a beat of 14.5%.
Analysts rate Crispr Therapeutics AG a buy (13 buy, 9 hold, 0 sell out of 22) with an average price target of $87.50.
| Fund | Stake |
|---|---|
| ARK Investment Management LLC | 9.78% |
| BlackRock Inc | 8.63% |
| Orbis Allan Gray Ltd | 5.64% |
| Capital World Investors | 4.91% |
| State Street Corp | 4.47% |
| GSK PLC | 3.33% |
| Geode Capital Management, LLC | 2.60% |
| T. Rowe Price Investment Management,Inc. | 2.12% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 CRISPR THERAPEUTICS AG - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash and marketable securities: $2,364.4 million (June 30, 2026) vs. $1,975.8 mil | 2026-08-03 |
| Results announced · Q3 2026 CRISPR THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • CASGEVY Revenue: $76 million in Q2 2026, up 78% quarter-over-quarter and 151% year- | 2026-08-03 |
| Board / officer change · Q2 2026 CRISPR THERAPEUTICS AG – 8-K SUMMARY HEADLINE NUMBERS • Annual General Meeting held June 4, 2026 • 70,716,663 votes FOR approval of 2025 financial s | 2026-06-04 |
| Quarterly report · Q1 2026 CRISPR THERAPEUTICS AG – FORM 10-Q SUMMARY Quarter Ended March 31, 2026 --- HEADLINE NUMBERS • Cash and marketable securities combined: $2,441.8 mi | 2026-05-04 |
| Results announced · Q2 2026 CRISPR THERAPEUTICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash Position: $2,441.8 million in cash, cash equivalents, and marketable s | 2026-05-04 |
| Proxy statement · Q2 2026 CRISPR THERAPEUTICS AG – PROXY SUMMARY FOR SHAREHOLDERS --- CEO COMPENSATION • Samarth Kulkarni, Ph.D. serves as both Chairman and Chief Executive | 2026-04-21 |
| Material agreement · Q1 2026 CRISPR THERAPEUTICS AG – 8-K SUMMARY HEADLINE NUMBERS • $600.0 million in Convertible Senior Notes issued (including full exercise of $50.0 million | 2026-03-16 |
| Annual report FY2025 CRISPR THERAPEUTICS AG – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Company: CRISPR Therapeutics AG, Swiss biopharmaceutical company, trad | 2026-02-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Crispr Therapeutics AG — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.